Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia.
Standardized definitions of response and outcome are useful to evaluate study data, facilitate treatment guideline adherence and aid clinical decision-making. Although definitions of response in chronic myeloid leukemia (CML) have been standardized, definitions of disease progression have not been standardized, despite widespread adoption of the term to reflect development of advanced disease. This article reviews definitions of response and disease progression used for progression-free survival and event-free survival in key CML studies and implications for interpreting patient response. It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making.
Washington University of St. Louis, St. Louis, MO 63110, USA.
George
G
Ansstas
Ravi
R
Vij
D018450:Disease Progression; D018572:Disease-Free Survival; D019983:Guideline Adherence / Q000592:standards; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D017063:Outcome Assessment, Health Care / Q000592:standards* / Q000639:trends; D017410:Practice Guidelines as Topic / Q000592:standards; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases